The post-hoc analysis of phase III randomized clinical trials showed that BAFF levels ≥ 2 ng/ml at enrollment were an independent prognostic factor for an increased risk of moderate and severe lupus flares in patients randomized to receive standard therapy only (Petri et al., 2013). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.